NSRX NASUS PHARMA LTD revenue, earnings and financials
For the fiscal year ended December 2025 revenue was $1.24B.
NSRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.24B, gross profit n/a, operating income −$4.90M, net income −$5.86M (margin -0.5%), EPS −$0.72
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$1.08M, net income −$1.53M (margin n/a), EPS −$0.22
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$1.15M, net income −$1.05M (margin n/a), EPS −$0.20
NSRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.92M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$665K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.03M, share buybacks n/a
NSRX balance sheet
- Dec 31, 2025: cash $1.24M, total assets $5.00M, total liabilities $2.24M, shareholders' equity $2.77M
- Dec 31, 2024: cash $284K, total assets $717K, total liabilities $3.93M, shareholders' equity −$3.21M
What is NSRX's revenue?
NASUS PHARMA LTD reported $1.24B of revenue for the fiscal year ended December 2025.
Is NSRX profitable?
No. NASUS PHARMA LTD lost $5.86M in its latest fiscal year.